Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropeginterferon plus bosutinib in newly diagnosed chronic phase CML
2018-001044-54Phase 2Active
- Sponsor
- St. Olavs University Hospital
- Start
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ropeginterferon alfa-2b in chronic myelogenous leukemia (CML), sponsored by St. Olavs University Hospital. Started Jul 2018; status: active.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2018-001044-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001044-54.